STOCK TITAN

Arch Therapeutics Inc - ARTH STOCK NEWS

Welcome to our dedicated news page for Arch Therapeutics (Ticker: ARTH), a resource for investors and traders seeking the latest updates and insights on Arch Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Arch Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Arch Therapeutics's position in the market.

Rhea-AI Summary
Arch Therapeutics, Inc. (OTCQB: ARTH) reported strong trends in orders and paid claims for its AC5 Advanced Wound System, with a significant increase in orders, favorable coverage and reimbursement decisions, and a doubling of September orders compared to August. The company also highlighted key milestones and achievements from the fiscal year ended September 30, 2023, including the establishment of a dedicated HCPCS code for AC5, the creation of a Medical Advisory Board, and successful presentations at the Symposium on Advanced Wound Care.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.98%
Tags
none
-
Rhea-AI Summary
Arch Therapeutics announced that its first commercial product, AC5 Advanced Wound System, will be featured at the 2023 Symposium on Advanced Wound Care Fall Meeting. The product will be showcased in a clinical case poster and a hands-on skills lab for clinicians. The poster will present a case study demonstrating the use of AC5 in patients with chronic venous leg ulcers. The hands-on skills lab will provide clinicians with the opportunity to learn and gain hands-on experience with AC5.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.05%
Tags
conferences
-
Rhea-AI Summary
Orders and paid claims for Arch Therapeutics' AC5 Advanced Wound System have increased since the rollout of the reimbursement code A2020, with average monthly order volume growing over four-fold compared to the first quarter. The company has confirmed reimbursement through paid claims in various regions and continues to work on expanding coverage and optimizing payment policies. While total revenue remains modest, the increase in order volume and reimbursement trends exceed management's targets. AC5 is FDA-cleared for the management of partial and full-thickness wounds.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
192.79%
Tags
none
Rhea-AI Summary
Arch Therapeutics completes private placement preceding planned national exchange listing of common stock
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.09%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.67%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.94%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10%
Tags
none
Arch Therapeutics Inc

OTC:ARTH

ARTH Rankings

ARTH Stock Data

5.30M
2.81M
25.13%
25.3%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States
Framingham

About ARTH

arch therapeutics, inc., together with its subsidiaries, operates as a biotechnology company in the united states. the company develops and markets products based on its ac5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. its flagship products include ac5 advanced wound system and ac5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. the company was founded in 2006 and is based in framingham, massachusetts.